Loading
institutionsInstitution
Instituto Português de Oncologia de Lisboa Francisco Gentil
Portugal's first cancer institute, founded in 1923 by Francisco Gentil, and the national reference cancer hospital for the Lisbon region.
Also called: IPO LisboaIPO-LisboaInstituto Português de Oncologia
Overview
The Instituto Português de Oncologia was founded in Lisbon in 1923 by the surgeon Francisco Gentil and gave rise to the national IPO network; IPO Lisboa remains the country's largest dedicated cancer hospital and is OECI-accredited. It provides surgical, medical, radiation and paediatric oncology, haematology and bone marrow transplantation, nuclear medicine and palliative care, and hosts a research unit working on molecular pathology, haematological malignancies and cancer epidemiology, together with Portugal's southern regional cancer registry. Patients access national referral services for rare tumours, sarcoma and paediatric cancers and a growing clinical trials programme.
Location
Lisbon, PT
Type
cancer center · Universidade de Lisboa
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#233 · 26 points (0 Newsweek + 0 NCI + 26 from 13 linked objects) · ranking
- National cancer hospital
- Haematology and transplantation
- Paediatric oncology
- Rare tumours and sarcoma
- Regional cancer registry
Carla Gonçalo
Presidente do Conselho de Administração (Chair of the Board of Directors) of IPO Lisboa
Health services managementHospital governancePublic health administration
Health manager who chairs the board of IPO Lisboa, the Portuguese Oncology Institute in Lisbon, since the board took office in 2025.
Júlio Oliveira
Presidente do Conselho de Administração (Chair of the Board of Directors) of IPO Porto
Medical oncologyCancer centre managementClinical research
Medical oncologist who chairs the board of IPO Porto, the public cancer hospital serving northern Portugal, since 2022.
Maria Margarida Torres de Ornelas
Presidente do Conselho de Administração, Instituto Português de Oncologia de Coimbra Francisco Gentil, E.P.E.
Hospital administrationCancer care management
Chair of the board of directors of IPO Coimbra, the Portuguese public oncology institute in Coimbra, reappointed with her board for the 2024 to 2026 mandate.
Similar pages
- InstitutionTawam Hospital
Shares Allogeneic (off-the-shelf) cell therapy, Acute lymphoblastic leukaemia, IMRT / IGRT (modern external beam), HR-positive / HER2-negative breast cancer.
- InstitutionKing Hussein Cancer Center
Shares Allogeneic (off-the-shelf) cell therapy, PET/CT, Acute lymphoblastic leukaemia, HR-positive / HER2-negative breast cancer.
- InstitutionHospital Universitari i Politècnic La Fe
Shares Allogeneic (off-the-shelf) cell therapy, PET/CT, Acute lymphoblastic leukaemia, HR-positive / HER2-negative breast cancer.
- InstitutionRamathibodi Hospital, Mahidol University
Shares Allogeneic (off-the-shelf) cell therapy, Acute lymphoblastic leukaemia, HR-positive / HER2-negative breast cancer, Colorectal cancer.
- InstitutionChildren's Cancer Hospital Egypt 57357
Shares Allogeneic (off-the-shelf) cell therapy, Sarcomas (soft tissue, bone, GIST), Acute lymphoblastic leukaemia, IMRT / IGRT (modern external beam).
- InstitutionTata Medical Center, Kolkata
Shares Allogeneic (off-the-shelf) cell therapy, Acute lymphoblastic leukaemia, IMRT / IGRT (modern external beam), HR-positive / HER2-negative breast cancer.
- InstitutionNational Cancer Institute, Cairo University
Shares Allogeneic (off-the-shelf) cell therapy, Acute lymphoblastic leukaemia, IMRT / IGRT (modern external beam), HR-positive / HER2-negative breast cancer.
- InstitutionRambam Health Care Campus
Shares Allogeneic (off-the-shelf) cell therapy, IMRT / IGRT (modern external beam), HR-positive / HER2-negative breast cancer, Colorectal cancer.